<DOC>
	<DOCNO>NCT02778893</DOCNO>
	<brief_summary>Our study NSCLC harbor EGFR-mutation Conmana combine thalidomide first-line treatment , expect improve EGFR-Tyrosine kinase inhibitor ( TKI ) response rate ( ORR ) , prolong time progression ( PFS ) , improve patient survival .</brief_summary>
	<brief_title>Conmana Combined With Thalidomide Treat NSCLC</brief_title>
	<detailed_description>Primary Objective : To evaluate efficacy , survival side effect combine therapy , evaluate effectiveness safety thalidomide Conmana patient harbor EGFR mutation .</detailed_description>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Patients must ability understand willingness sign write informed consent document . 2 . Patients age &gt; 18 year &lt; 75 year . Patients must Life Expectancy great 3 month . 3 . Patients must NSCLC confirm Histological cytological . 4 . Eastern Cooperative Oncology Group ( ECOG ) score standard : 02 . 5 . Patients must normal organ marrow function define , within two week prior study : absolute neutrophil count &gt; 1,500/mL platelet &gt; 100,000/mL total bilirubin : within normal institutional limit Aspartate transaminase ( AST ) /Alanine aminotransferase ( ALT ) &lt; 2.5 time institutional upper limit normal creatinineâ‰¤1.5 time institutional upper limit normal urine dipstick proteinuria &lt; le 1+ . If urine dipstick &gt; 1+ 24 hour urine protein must demonstrate &lt; 500mg protein 24 hour allow participation study . 6 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 7 . Judging researcher , patient comply program . 1 . Women pregnant breastfeeding Note : Pregnant woman exclude study agent use study may teratogenic fetus . Because unknown potential risk adverse event nurse infant secondary treatment mother thalidomide , breastfeed woman also exclude study . 2 . During course treatment , serious active infection intravenous injection antibiotic require . 3 . Patients history allergic reaction attribute compound similar chemical biologic composition thalidomide icotinib agent use study exclude . 4 . A person effectively control , symptom brain metastasis , suffers mental disorder easily control ; severe mental cognitive impairment . 5 . Congestive heart failure , arrhythmia , myocardial infarction , unstable angina , stroke transient ischemic attack 6 month . 6 . 5 year suffer malignancy , except treatment cervical carcinoma situ skin squamous cell carcinoma skin , basic control skin basal cell carcinoma . 7 . Can follow test program meet followup patient . 8 . The researcher think appropriate participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Conmana</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>NSCLC</keyword>
	<keyword>EGFR mutation</keyword>
</DOC>